Key Highlights
- Investors are balancing a mixed analyst outlook ahead of a pivotal FDA advisory committee meeting on peptides scheduled for July 23-24.
- BofA recently raised its price target to $37 while Canaccord sits at $40, but Truist maintained a Hold with a $23 target citing peptide uncertainty.
- Last week's 6% pullback reflected softer-than-expected retention for oral GLP-1 members and ongoing gross margin compression concerns, even as full-year guidance was raised to $2.8-$3 billion.
Hims & Hers Health (NYSE: HIMS) shares are trading flat flat near $34.47 today, moving in line with the broader healthcare sector, as investors weigh a mix of company-specific catalysts and broader macro developments.
Investors are balancing a mixed analyst outlook ahead of a pivotal FDA advisory committee meeting on peptides scheduled for July 23-24. BofA recently raised its price target to $37 while Canaccord sits at $40, but Truist maintained a Hold with a $23 target citing peptide uncertainty.
Last week's 6% pullback reflected softer-than-expected retention for oral GLP-1 members and ongoing gross margin compression concerns, even as full-year guidance was raised to $2.8-$3 billion.
Today's move is also unfolding against a broader risk backdrop, as renewed U.S.-Iran hostilities have sent oil prices sharply higher and injected a risk-off tone across equity markets. The healthcare sector, tracked by the XLV ETF, is itself navigating this volatile macro environment, with investors weighing geopolitical headline risk alongside company-specific fundamentals heading into a pivotal earnings season.
Looking ahead, investors will be watching how Hims & Hers Health's next earnings report and any further analyst commentary shape the stock's trajectory, particularly as markets continue to digest both company-specific catalysts and the broader macro backdrop of geopolitical tension and shifting interest rate expectations.
FAQs
Q: Why is Hims & Hers Health (HIMS) stock moving today?
A: Investors are balancing a mixed analyst outlook ahead of a pivotal FDA advisory committee meeting on peptides scheduled for July 23-24.
Q: What are analysts saying about HIMS?
A: Investors are balancing a mixed analyst outlook ahead of a pivotal FDA advisory committee meeting on peptides scheduled for July 23-24.
Q: What should investors watch next for Hims & Hers Health?
A: Investors are watching upcoming earnings reports and further analyst commentary, alongside the broader macro backdrop of geopolitical tension and shifting interest rate expectations, for the next signal on HIMS's direction.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.